A clinical-stage biotechnology company announced it is starting a phase 2a trial of its lead candidate for the treatment of alcohol use disorder, according to a company press release.
The study is based on positive phase 1 results of the intranasal psychedelic compound 5-MeO-DMT (BPL-003, Beckley Psytech). The data established BPL-003 to be well-tolerated with a reproducible and dose-linear pharmacokinetic profile, according to the release.
To test BPL-003, researchers at King’s College London will administer a single dose of the psychedelic to patients with alcohol use disorder. Patients